Pharmaceutical companies use Feel Therapeutics’ technology to monitor the mental state of participants in clinical trials of behavioral medications. But the startup envisions its technology eventually also finding a place as a part of clinical care.
Novocure said its “Tumor Treating Fields” met the main goal of a pivotal study enrolling non-small cell lung cancer patients with brain metastases. However, results for the electricty-based treatment fell short of statistical significance on several secondary endpoints.
Fractyl Health will use the IPO proceeds for pivotal testing of a medical device and surgical procedure intended to address root causes of diabetes and obesity. The Fractyl pipeline also includes a gene therapy for these conditions.
Medical device giant Boston Scientific added to its string of recent acquisitions by announcing its plan to buy Axonics, a maker of neurostimulation devices that treat urinary and bowel dysfunction, for $3.7 billion. Experts agree that this deal will make a profitable impact on Boston Scientific’s urology business.
Abbott's new leadless pacemaker system has become commercially available and has begun being implanted in people at hospitals across the nation. Most people who need a pacemaker require pacing in two chambers of the heart, and the dual-chamber technology in Abbott's new system allows these patients to have a leadless pacemaker.
With its new handheld ultrasound device, Exo is seeking to take point-of-care ultrasound beyond just the emergency medicine field — into areas like urgent care, primary care and the home. Kurt Hammond, Exo's chief commercial officer, said that the device sets itself apart from other handheld ultrasound devices, such as those sold by GE, Philips and Butterfly Network, because its AI does a better job of making the ultrasound process quick and easy for providers.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Intarcia Therapeutics’ GLP-1 agonist product candidate for type 2 diabetes now belongs to i2o Therapeutics, which will make the treatment’s case for approval at an upcoming FDA advisory committee meeting. The startup’s $46 million Series A financing is one of several recently announced funding rounds.
Israeli health tech fund Shoni Health Ventures recently launched to invest in digital health and medical device startups that are in the pre-seed and seed stages of fundraising. The fund is affiliated with Sheba Medical Center, the largest hospital in Israel. Startups will have access to the hospital’s innovation center so that they can develop, pilot and commercialize their products.
Cala Health recently launched its kIQ system — which it calls the first noninvasive wearable device cleared by the FDA to temporarily relieve tremors in people with essential tremor and Parkinson’s disease.
Know Labs recently unveiled the prototype for its non-invasive, portable glucose monitoring device. The device incorporates the company's proprietary body-radio frequency identification (Bio-RFID) technology — meaning its sensors deploy radio waves that travel through the skin to find and measure molecular signatures in the blood.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Robert Lewis is the founder of Freedom to Roam, a medical device company seeking to help people with mobility challenges.
Israeli medical device developer Magenta Medical recently closed a $55 million financing round. The new funding will be used primarily to help Magenta attain FDA approval for its flagship product — a percutaneous left ventricular assist device called Elevate.
Healthcare investment firm Patient Square Capital launched a new portfolio company: Elevage Medical Technologies. The company will support growth-stage medical device companies by providing capital, as well as operational and clinical expertise — it received an initial investment of $300 million from Patient Square.
Consumers are demanding the constant need for technology that is simple, connected and convenient, and medtech companies have had to accelerate to meet those needs. They are embracing these changing times and using it as an opportunity to innovate in three key areas.
Nvidia and Medtronic recently announced a collaboration focused on embedding AI into medical devices. The two companies plan to create marketplace for AI applications that will allow developers and clinicians to develop their own algorithms to use on Medtronic’s medical devices.
